Cereno Scientific

“CS014 continues to strengthen the value of our HDAC inhibitor platform, supported by a growing body of non-clinical and early clinical data and our first peer-reviewed publication. With its disease-modifying potential and differentiated mechanism of action, CS014 represents an important asset in our pipeline and have a significant potential to deliver unprecedented value to patients with cardiovascular and pulmonary disease,” said Sten R. Sörensen, CEO at Cereno Scientific.

Poster presentation: CS014, a Novel Precision Deuterated VPA with HDAC Inhibitor Properties, Demonstrates Preclinical Efficacy in Pulmonary Vascular Disease and Clinical Safety

• Presenting author: Dr Tatiane Dall’Agnol
• Paper Number: 147
• Session details: Day 2: Moderated poster discussion – Robinson – on Friday, Jan 30, 2026, at 15:10 - 16:15 (GMT) in the Robinson Suite.

Panel: A Withdrawal Study in PAH: A regulatory, clinical, & patient perspective

• Speakers: Regulatory viewpoint: Norman Stockbridge (remote); Clinician viewpoint: Ardeschir Ghofrani; Patient viewpoint: Iain Armstrong
• Facilitators: Björn Dahlöf & Wendy Gin-Sing
• Session details: Wednesday, Jan 28, 11:30-12:10 (GMT) in the Higgins 1+2 Rooms

The Pulmonary Vascular Research Institute (PVRI) is a professional organization and charity with over 6,000 scientists, researchers, doctors, pharmaceutical companies, drug regulators, healthcare practitioners, patients, family members and those with a specific interest in pulmonary hypertension (PH) spanning over 100 countries. It is the only not-for-profit membership organisation dedicated entirely to enhancing pulmonary vascular disease research and education globally. The Annual Congresses are pivotal gatherings for experts in pulmonary vascular disease, offering a dynamic platform for interdisciplinary dialogue and innovation. Through keynote lectures, scientific presentations, and networking sessions, attendees collaborate on cutting-edge research and emerging therapies, ultimately aiming to improve patient care and outcomes globally. The congresses play a crucial role in fostering international collaboration, translating research into practice, and advocating for greater awareness and resources in the field. More information about the scientific conference is available on: https://pvrinstitute.org/learning-hub/events/pvri-2026-dublin

The scientific poster will be available on Cereno Scientific’s webpage after the conference conclusion.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About CS014

CS014 is being developed as a next-generation HDAC inhibitor and novel chemical entity designed to modulate epigenetic pathways that target the root cause of cardiovascular and pulmonary diseases. Non-clinical studies have demonstrated potent effects on pathways involved in vascular remodeling, fibrosis and thrombosis, which are key drivers of disease progression in several cardiovascular and pulmonary conditions and suggests disease-modifying potential (Stanger, L. et al (2025). The recently completed Phase I study confirmed that CS014 has a favorable safety profile and is well tolerated at and above exposure levels that, based on non-clinical data, are predicted to support maximal effects on the reversal of pulmonary vascular remodeling and fibrosis. These findings support advancement of CS014 into Phase II clinical development. Cereno Scientific is advancing CS014 as a potential new treatment for patients with severe, progressive cardiovascular and pulmonary diseases that currently lack effective therapies.

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company’s innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling, improvement of right heart function and enhanced patient quality of life in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.